Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] LigaChem Biosciences (141080) – IBK Securities | Enhertu Resistance · Clinical Readouts · Tech Transfer / 2025-11-27 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | Memory Pricing · Earnings Upgrades · LTA / 2026-04-02 Research
  • [Research] Samsung Biologics (207940) – Yuanta Securities | US Site Acquisition · Biosecure Act Beneficiary · Plant 6 & Campus 3 Expansion / 2026-01-07 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Low-Price Mix Reduction · Merchant Margin Step-Up · MASGA & Defense Pipeline / 2026-04-28 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Keytruda SC Growth Accelerates · Favorable Contract Terms · Early June PGR Catalysts / 2026-05-11 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · High-Value Memory · Pricing Momentum / 2026-04-24 Research
  • [Research] Samsung Biologics (207940) – iM Securities | New Plant Operations · PolyPeptide Acquisition · Portfolio Diversification / 2026-07-24 Research
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Server Memory Demand · HBM3E Pricing · Margin Expansion / 2026-01-30 Research

[Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM · eSSD · Margin Expansion / 2026-01-30

Posted on January 30, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Eugene Investment & Securities

Analyst : Sojung Yim

Investment Rating : BUY (Maintained)

Target Price : 1,170,000 KRW (Raised)

Core Momentum : Strong demand for high-value HBM and enterprise SSD products amid structurally tight supply is expected to drive further profitability gains, supporting the prospect of SK hynix reaching a 60% operating margin in 2026.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price: 1,170,000 KRW (Based on Target P/B 2.5x applied to 2027F Fwd BPS, Raised)
  • Investment Rating: BUY (Maintained)
  • 2026E Financial Outlook: Revenue 194.06 trillion KRW, Operating Profit 130.63 trillion KRW, Net Income 108.55 trillion KRW
  • EPS: 149,068 KRW (2026E)
  • Valuation Multiples: PER 5.8x, PBR 2.8x, EV/EBITDA 3.7x, ROE 64.6% (Based on 2026E)

🚀 2. [Market Opportunities & Business Outlook]

  • 4Q25 Review: Revenue reached 32.8 trillion KRW (+66% YoY, +34% QoQ) and operating profit hit 19.2 trillion KRW (+137% YoY, +68% QoQ), beating market consensus and setting a new all-time quarterly record with an operating margin of 58.4%.
  • Margin Outlook: SK hynix is positioned to potentially become the first global memory supplier to achieve an operating margin in the 60% range in 2026, driven primarily by high-value server product demand centered on HBM.
  • Supply Dynamics: NAND profitability is recovering sharply on the back of growing eSSD shipments, while supply-side tightness continues due to natural reduction during advanced node transitions and legacy product EOL, fostering a structural improvement trend.
  • Investment & Returns: The management comment on investment-to-revenue ratio reflects the 2024 value-up filing baseline (mid-30% range); reflecting recent earnings projections and market conditions, it is appropriate to interpret the current 2026 investment scale at the mid-to-high 20% level of revenue. Depending on cash flow conditions, the company is positively reviewing active shareholder return policies alongside CAPEX reinvestment.

📝 Editor’s Comment (Perspective)

The analyst views SK hynix as an enterprise enhancing its structural profitability—targeting a milestone 60% operating margin as the first global memory player—supported by a supply-advantaged environment centered on high-value HBM and eSSD server solutions. The analyst highlights disciplined investment execution alongside exceptional cash generation.

To verify this investment thesis, one should track whether the full-year 2026 operating margin reaches the 60% threshold, if CAPEX execution remains effectively controlled at the mid-to-high 20% level of revenue based on current projections, and how solid earnings and cash flows translate into concrete shareholder return policies. These indicators can be monitored through upcoming quarterly reports and regulatory filings via DART.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Shinhan | Memory ASP · Supply Tightness · Pricing Power / 2026-01-30
Next Post: [Research] SK hynix (000660 / SKHY) – Daishin | Capex Discipline · Multi-Year LTA · Shareholder Returns / 2026-01-30

Related Posts

  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI Server Demand · Supply Deficit · FCBGA Technical Bottleneck / 2026-07-20 Research
  • [Research] Samsung SDI (006400) – IBK Securities | ESS Shipment Expansion · AMPC Benefits · Profit Turnaround / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Contract Pricing · LTA · DRAM Supply Shortage / 2026-04-09 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | Commodity DRAM Pricing · LTA · Multiple Expansion / 2026-06-26 Research
  • [Research] Samsung SDI (006400) – Kiwoom Securities | Near-Term Sluggishness but Intact Momentum · 4Q26 Turnaround · Solid-State Pipeline / 2026-02-03 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | Memory Pricing · Earnings Upgrades · LTA / 2026-04-02 Research
  • [Research] ABL Bio (298380) – Yuanta Securities | Givastomig Efficacy · Bispecific ADC · Platform Valuation / 2026-01-29 Research
  • [Research] Samsung Electro-Mechanics (009150) – DS Investment & Securities | MLCC Price Leverage · Capacity Cannibalization · Earnings Upward Revisions / 2026-07-31 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Dual Up-cycle · Large-Scale CapEx · Target Price Upgrade / 2026-07-08 Research
  • [Research] Samsung SDI (006400) – Mirae Asset | Operating Profit Upgrades · Core Turnaround · Prismatic Competitiveness / 2026-07-31 Research
  • [Research] Samsung SDI (006400) – Hana Securities | North America JV Resolution · ESS Line Conversion · Earnings Estimate Upgrades / 2026-08-12 Research
  • [Research] LIG D&A (079550) – iM Securities | Premier Air Defense Scarcity · Target Price Upgrade · Global Inquiries / 2026-05-08 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | ESS Revenue Surge · 4Q26 Turnaround · Physical AI Expansion with 46-Series & All-Solid-State / 2026-02-03 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme